Vivian Wu leads Baker McKenzie FenXun's Investigations, Compliance & Ethics team in China and serves as the Chair of the Steering Committee of APAC Healthcare and Life Science Practice Group. Her practice focuses on China-related corporate regulatory and compliance matters, anti-corruption, data protection, and sanctions in particular. She has more than 20 years of experience in compliance investigations, due diligence, risk assessment, compliance programs and training. In 2020, Vivian was appointed as a member of the Foreign-related Attorney Talent Panel by Beijing Bar Association. In 2014, Vivian worked in the Firm's Washington DC office with the North American Compliance and Investigations Practice Group on China related regulatory and investigation matters.

Vivian has advised various US and European companies on managing the challenges associated with conflicts of law in trade compliance, including the requirements and implications of China countermeasures, the counterespionage law, and other national security related laws and regulations. As part of her extensive portfolio of compliance and investigation matters, she has represented a European headquartered global conglomerate in multiple internal investigations regarding various allegations on inventory stock, reimbursement fraud, and trade compliance violation. She has also assisted a US headquartered multinational medical device manufacturer in conducting a risk assessment regarding personal information protection, particularly the cross border data transfer related risks.

Vivian is recognized as a Leading Individual in Corporate Investigations/Anti corruption by Chambers Global (2025–2026) and Chambers Greater China (2022–2026), and as a Leading Individual in Regulatory/Compliance by The Legal 500 Asia Pacific (2025–2026). She is qualified to practice in China and New York State, and holds an LL.M. from Harvard Law School.